{"name": "Euthymics Bioscience",
 "permalink": "euthymics-bioscience",
 "crunchbase_url": "http://www.crunchbase.com/company/euthymics-bioscience",
 "homepage_url": "http://www.euthymics.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@euthymics.com",
 "phone_number": "617-674-3830",
 "description": "",
 "created_at": "Sat Jul 24 02:33:25 UTC 2010",
 "updated_at": "Thu May 30 14:01:23 UTC 2013",
 "overview": "\u003Cp\u003EEuthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics\u00e2\u20ac\u2122 initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       42],
      "assets/images/resized/0009/4756/94756v1-max-150x150.png"],
     [[221,
       62],
      "assets/images/resized/0009/4756/94756v1-max-250x250.png"],
     [[221,
       62],
      "assets/images/resized/0009/4756/94756v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO, Co-Founder",
    "person":
     {"first_name": "Anthony",
      "last_name": "A. McKinney",
      "permalink": "anthony-a-mckinney",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer, Co-Founder",
    "person":
     {"first_name": "Franklin",
      "last_name": "P. Bymaster",
      "permalink": "franklin-p-bymaster",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Thomas",
      "last_name": "A. Shea",
      "permalink": "thomas-a-shea",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$35M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.euthymics.com/pdf/2010.07.22%20Press%20Release%20-%20Euthymics%20Series%20A.pdf",
    "source_description": "EUTHYMICS BIOSCIENCE, INC. CLOSES $24 MILLION SERIES A FINANCING AND COMPLETES ACQUISITION OF DOV PHARMACEUTICAL",
    "raised_amount": 24000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 7,
    "funded_day": 22,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Hambrecht \u0026 Quist Capital Management",
         "permalink": "hambrecht-quist-capital-management",
         "image":
          {"available_sizes":
            [[[150,
               6],
              "assets/images/resized/0012/1275/121275v1-max-150x150.jpg"],
             [[250,
               11],
              "assets/images/resized/0012/1275/121275v1-max-250x250.jpg"],
             [[450,
               20],
              "assets/images/resized/0012/1275/121275v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.masshightech.com/stories/2011/03/07/daily34-Euthymics-Bioscience-bumps-Series-A-to-28M.html",
    "source_description": "Euthymics Bioscience bumps Series A to $28M",
    "raised_amount": 4000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 3,
    "funded_day": 9,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Venture Funds",
         "permalink": "novartis-ventures",
         "image":
          {"available_sizes":
            [[[150,
               14],
              "assets/images/resized/0004/4137/44137v1-max-150x150.png"],
             [[215,
               21],
              "assets/images/resized/0004/4137/44137v1-max-250x250.png"],
             [[215,
               21],
              "assets/images/resized/0004/4137/44137v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Venture Investors",
         "permalink": "venture-investors",
         "image":
          {"available_sizes":
            [[[150,
               40],
              "assets/images/resized/0006/2067/62067v1-max-150x150.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-250x250.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "H\u0026Q Venture Capital",
         "permalink": "h-q-venture-capital",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://finance.yahoo.com/news/neurovance-closes-7m-series-a1-113200571.html",
    "source_description": "Neurovance Closes $7M Series A1 Round for Development of EB-1020 for ADHD; Reports Phase 1 Clinical Trial Results",
    "raised_amount": 7000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 10,
    "funded_day": 18,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "35 Braintree Hill Office Park",
    "address2": "Suite 304",
    "zip_code": "02184",
    "city": "Braintree",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "added $4 million to its July, 2010, Series A financing round of $24 million, bringing the total raised by the company to $28 million",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2011/03/07/daily34-Euthymics-Bioscience-bumps-Series-A-to-28M.html",
    "source_text": null,
    "source_description": "Euthymics Bioscience bumps Series A to $28M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Euthymics Bioscience",
      "permalink": "euthymics-bioscience"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}